



SENIOR MANAGEMENT APPOINTMENT

Released : 06 Mar 2018 07:00

RNS Number : 7489G

Amryt Pharma PLC

06 March 2018

6 March 2018

AIM: AMYT

ESM: AYP

**Amryt Pharma plc
("Amryt" or the "Company")**

Senior Management Appointment

Amryt, a biopharmaceutical company focused on treatments for rare and orphan diseases, is pleased to announce the appointment of Jordi Casals as the Company's Head of Europe.

Jordi will be responsible for leading and further developing Amryt's European operations, including product launches. His initial focus is on the continuing sales growth of the Company's commercial asset, Lojuxta, a treatment for adult patients with Homozygous Familial Hypercholesterolaemia.

Jordi has over 20 years' experience in the pharmaceutical and biotech industry. Most recently, he worked for Aegerion Pharmaceuticals as a Consultant, managing its commercial operations in the Iberia region. Before that, he worked for eight years at Alexion Pharmaceuticals, latterly as VP Commercial Operations Western Europe. He has also held sales and marketing roles at Grifols S.A., the European multinational pharmaceutical, and Otsuka Pharmaceutical Europe, the Japan-based pharmaceutical company.

Jordi holds an MBA from UPC University, Barcelona, together with a Pharmacy Degree from Barcelona University.

Dr. Joe Wiley, Chief Executive Officer, commented:

"I am pleased to welcome Jordi to our senior management team as the Company's Head of Europe. His significant commercial experience of European markets will help us to drive and further develop Amryt's growth across this key region."

Enquiries:

Amryt Pharma plc

+353 (1) 518 0200

Joe Wiley, CEO

Rory Nealon, CFO/COO

KTZ Communications

+44 (0) 20 3178 6378

Katie Tzouliadis, Irene Bermont-Penn, Emma Pearson

About Amryt Pharma plc

www.amrytpharma.com

Amryt Pharma is a specialty biopharmaceutical company focused on developing and delivering innovative new treatments

to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

The Company holds an exclusive licence to sell Lojuxta (lomitapide) for adults, across the European Economic Area, Middle East and North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolaemia, which impairs the body's ability to remove LDL cholesterol ("bad" cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels, leading to aggressive and premature narrowing and blocking of arterial blood vessels. If left untreated, heart attack or sudden death may occur in childhood or early adulthood.

Amryt's lead drug candidate, AP101, is a potential treatment for Epidermolysis bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. It is currently in Phase III clinical trials. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion.

Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease.

The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.

This information is provided by RNS
The company news service from the London Stock Exchange

END

NRAQELFBVXFEBBF